Biotech

Selected news for the healthcare topic - Biotech, collected since 10/2017. Recent stories appear in MedCity News and Dakota Financial News. This healthcare topic shares news with COVID-19, COVID-19 Vaccine, Coronavirus, Pfizer, AstraZeneca and hundreds of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
7/21/2021 Bioinformatics Services Market : Indicates Impressive Growth Rate In HealthcareIT Industry PRSync ... management services, and other bioinformatics services. Due to reduced cost of sequencing the sequencing services segment enjoy the major share of the market. Based on specialty, the bioinformatics services market is segmented into medical biotech nology, plant biotech nology, animal biotech nology, environment biotech nology and forensic biotech nology. Medical biotech nology holds the largest share due to the development of new databases for drug discovery, the use of bioinformatics for clinical diagnostics, and increasing funding ...
7/21/2021 Avidity Biosciences CEO Reflects on Going Public in 2020 sdbj.com BIOTECH: SARAH BOYCE SPEAKS ABOUT COMPLETELY VIRTUAL IPO PROCESS Avidity Biosciences CEO Reflects on Going Public in 2020 Tuesday, July 20, 2021 Boyce said that the past year has changed everything about what it means for a biotech company to go public. “We did the IPO, end to end completely virtually,” she said. “And it’s interesting in that when we set our plans for the IPO and the ...
7/21/2021 IM Therapeutics posts positive, early results for oral Type 1 diabetes hopeful FierceBiotech ... and is seen in a majority of patients, IM said Wednesday.Human leukocyte antigens (HLAs) are the "earliest triggers of autoimmune disease," said Nandan Padukone, Ph.D., CEO of IM, in an interview with Fierce Biotech . HLAs recognize natural proteins like insulin, myelin, collagen and others in autoimmune diseases as foreign and then attacks them.IM is "knocking out that very first step" in autoimmune diseases by attempting to block off ...
7/21/2021 Vedanta raises $68M, reveals setback to Bristol Myers alliance FierceBiotech Vedanta Biosciences has raised $68 million to take a microbiome candidate into phase 3. The biotech also used the series D update to reveal the failure of its Bristol Myers Squibb checkpoint inhibitor alliance to generate data to support further development.Massachusetts-based Vedanta is developing oral drugs that are designed to deliver defined bacterial consortia to treat diseases linked to the microbiome. With interest in the concept riding high ...
7/21/2021 Coave raises $25M ahead of pivotal retinal gene therapy trial FierceBiotech Coave Therapeutics has added €21.2 ($25.0 million) million to its series B round, setting the French biotech up to move a gene therapy against PDE6b inherited retinal dystrophies toward pivotal trials.In November 2017, Paris-based Coave, formerly known as Horama, took a therapy designed to deliver a nonmutated copy of the PDE6B gene to retinitis pigmentosa patients into a phase 1/2 clinical trial. The following year, led by ...
7/21/2021 Albireo's rare liver disease drug Bylvay scores back-to-back approvals in U.S., Europe FiercePharma With a pair of approvals on both sides of the Atlantic, liver disease-focused biotech Albireo is off and running with its new medicine Bylvay.The oral drug, the first treatment for pruritus in patients with progressive familial intrahepatic cholestasis (PFIC), scored an FDA nod Tuesday and a European approval Monday. With the FDA's blessing, Albireo is kicking off an "immediate" launch.Analysts with Evaluate Pharma have predicted the drug ...
7/20/2021 Panakès Partners Announces the First Closing Of Its New 'Purple' Global Biotech/ Medtech Fund at €150 Million ($180 Million) PR Newswire ... and pension funds, as well as numerous Italian companies and family offices in the Life Sciences sector. These include Menarini, the Cogliati family (Elemaster Group), the Colombo family (SAPIO Group), the Rovati family (Rottapharm Biotech), the Petrone family (Petrone Group), the Re family (Digitec Group), the Bassani family (Movi Group) and others.The Purple Fund will invest mainly in Series A funding rounds, as well as later stage opportunities. The ...
7/20/2021 Panakès Partners Announces the First Closing Of Its New 'Purple' Global Biotech/ Medtech Fund at €150 Million ($180 Million) PR Newswire Panakès will use the successful closing of its second Fund to extend its investment activity to biotech, while maintaining its ongoing activity in medtech, the focus of Panakès first fund Panakès plans to invest the new fund in companies at the forefront of global innovation with the potential to transform patient care, with a focus on Europe , and Italy in particular Panakès' Purple Fund has been ...
7/20/2021 Panakès Partners Announces the First Closing Of Its New 'Purple' Global Biotech/ Medtech Fund at €150 Million ($180 Million) tmcnet.com TMCnet News [July 20, 2021] Panakès Partners Announces the First Closing Of Its New 'Purple' Global Biotech/ Medtech Fund at €150 Million ($180 Million) - Panakès will use the successful closing of its second Fund to extend its investment activity to biotech, while maintaining its ongoing activity in medtech, the focus of Panakès first fund - Panakès plans to invest the new fund in companies at the ...
7/20/2021 A Pilot Study Of Warm And Cold Compress To Reduce Injection Site Erythema Due To Peginterferon digiblogbox.com ... the Crimean War. Nightingale needed Blackwell to turn her focus to training nurses, and could not see the legitimacy of training female physicians. Johnson & Johnson Honored In Fast Company’s Top Ten Most Innovative Biotech Companies While this image representsone frequent biotech nology career path, lab work is not the only possibility. With many exciting discoveries to make and new issues to solve, biotech nology professionals can make a distinction in the ...
7/20/2021 Panakès Partners Announces the First Closing Of Its New 'Purple' Global Biotech/ Medtech Fund at €150 Million ($180 Million) tmcnet.com Panakès Partners Announces the First Closing Of Its New 'Purple' Global Biotech/ Medtech Fund at €150 Million ($180 Million) - Panakès will use the successful closing of its second Fund to extend its investment activity to biotech, while maintaining its ongoing activity in medtech, the focus of Panakès first fund - Panakès plans to invest the new fund in companies at the forefront of global innovation with ...
7/20/2021 BenchSci Expands Board of Directors With Appointment of Life Sciences, Tech, and Healthcare Leader Luba Greenwood tmcnet.com ... July 20, 2021 /PRNewswire/ -- BenchSci , an emerging global leader in machine learning applications for novel medicine development, today announced that Luba Greenwood has joined its board of directors. Greenwood is a life sciences and biotech expert who lectures at Harvard University in the School of Engineering and Applied Sciences. She recently served as an executive at Google Life Sciences (Verily) and as Vice President of Global Business Development and Mergers ...
7/20/2021 BenchSci Expands Board of Directors With Appointment of Life Sciences, Tech, and Healthcare Leader Luba Greenwood tmcnet.com ... July 20, 2021 /PRNewswire/ -- BenchSci , an emerging global leader in machine learning applications for novel medicine development, today announced that Luba Greenwood has joined its board of directors. Greenwood is a life sciences and biotech expert who lectures at Harvard University in the School of Engineering and Applied Sciences. She recently served as an executive at Google Life Sciences (Verily) and as Vice President of Global Business Development and Mergers ...
7/20/2021 BenchSci Expands Board of Directors With Appointment of Life Sciences, Tech, and Healthcare Leader Luba Greenwood PR Newswire TORONTO BenchSci , an emerging global leader in machine learning applications for novel medicine development, today announced that Luba Greenwood has joined its board of directors.Continue ReadingLuba Greenwood joins BenchSci board of directorsGreenwood is a life sciences and biotech expert who lectures at Harvard University in the School of Engineering and Applied Sciences. She recently served as an executive at Google Life Sciences (Verily) and as Vice President ...
7/20/2021 STAT+: Three pharma wholesalers reach a $1.1 billion deal with New York over the opioid crisis STAT ... be announced this week. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! Log In Learn More What is it? STAT+ is STAT's premium subscription service for in-depth biotech , pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley ...
7/20/2021 In an unusual crossover, Gilead hires Arcus CMO Grossman, putting him in charge of cancer pact with his former biotech FierceBiotech Bill Grossman is leaving Arcus Biosciences to take up a position at Gilead, putting him in charge of the Big Pharma's collaboration with his former employers.Grossman is currently chief medical officer at Arcus. Effective July 26, he will transition to the role of SVP of oncology clinical research at Gilead. The Foster City, California-based biopharmaceutical company is tasking Grossman with leading co-development and co-commercialization of the ...
7/20/2021 Panakès moves into biotech investing with new €150M fund FierceBiotech Panakès has raised a €150 million ($177 million) fund that will extend its focus beyond medtech and into biotech. The VC shop will mainly use the money to invest in the series A rounds of European biotech and medtech startups, with a particular focus on its home country of Italy.Milan-based Panakès set up shop in 2015 with a focus on medtech investing. The focus reflected ...
7/20/2021 Ardelyx stock craters as FDA slaps biotech with dreaded ‘deficiencies’ tag on kidney drug FierceBiotech ... plan to work with the FDA to learn more about the identified deficiencies and will seek to resolve them as quickly as possible.”Shares were down more than 70% Monday evening when the biotech dropped the news after normal trading hours. The shares, which closed the day before at $7.70, were trading down 74% at $1.99 in pre-market trading Tuesday as the fallout continued ...
7/20/2021 Rivus’ fat-trimming therapy nabs $35M to harness our own biology against a host of diseases FierceBiotech Rivus Pharmaceuticals is going after an alphabet soup of diseases: Type 2 diabetes; severe hypertriglyceridemia (SHTG); non-alcoholic steatohepatitis (NASH); and heart failure with preserved ejection fraction (HFpEF).These are just the start for the little biotech as it nabs $35 million for a big push into the clinic.The series A for the Charlottesville, Virginia-based startup was co-led by Longitude Capital and Medicxi, with help from RxCapital ...
7/20/2021 Amylyx raises $135M to gear up for potential Canadian launch of ALS drug FierceBiotech ... picked up $135 million to bankroll a potential commercial launch and support a pipeline of other candidates for neurodegenerative diseases, including the one causing a stir this summer: Alzheimer's disease.The Cambridge, Massachusetts-based biotech raked in the oversubscribed series C Tuesday to support the clinical development and launch plans, pending a Canadian green light for the amyotrophic lateral sclerosis (ALS) treatment. The novel combination of compounds called AMX0035 was ...